4th Pediatric Infectious Diseases Conference
 
 
Home  Back   ISSN 0973 - 0958
 
User name :
Password :
FIND DIAGNOSIS
FIND DIAGNOSIS
Find Diagnosis
Pedi Poll
Today's Poll
Should teicoplannin, colistin be used in case of neonatal sepsis where culture does not reveal any organism_?
No, it should be used only after drug sensitivity report
Yes, under guidance of an infectious disease expert
CURRENT H1N1 INFLUENZA EPIDEMIC- RECENT UPDATE
H1N1 Influenza Epidemic
Swine Flu Influenza Treatment
Treatment
Bhushan Katira
Medical Sciences Department, Pediatric Oncall. Mumbai

Address for Correspondence: Bhushan Katira, 171/11, Basant Vihar Chs, R. B. Mehta Rd., Ghatkopar (E), Mumbai - 400077. Email: drbhushankatira@gmail.com

Continued...

Treatment:

  f. Medications:
CDC has approved the use of antiviral agents like Oseltamivir and Zanamivir whereas drugs like amantadine and rimantadine are to be used since the virus is resistant to them. Antiviral treatment with zanamivir or oseltamivir should be initiated as soon as possible after the onset of symptoms. Evidence for benefits from treatment in studies of seasonal influenza is strongest when treatment is started within 48 hours of illness onset. However, some studies of treatment of seasonal influenza have indicated benefit, including reductions in mortality or duration of hospitalization even for patients whose treatment was started more than 48 hours after illness onset. Recommended duration of treatment and prophylaxis is shown in Table 1, 2 & 3.

Table 1. Recommended doses of zanamivir and oseltamivir antiviral medications for the treatment of influenza A and B in children 1-18 years-old

  1-6 years 7-18 years
Zanamivir -
10 mg (2 inhalations) twice daily for 5 days
Up to 15 kg
15-23kg
23-40 kg
>40kg
Oseltamivir
30 mg twice a day for 5 days
45 mg twice a day for 5 days
60 mg twice a day for 5 days
75 mg twice a day for 5 days

Table 2: Recommended doses of zanamivir and oseltamivir antiviral medications for the prophylaxis of influenza A and B in children 1-18 years-old

 
1-4 years
5-18 years
Zanamivir
-
10 mg (2 inhalations) once daily for 10 days after the last known exposure
Up to 15 kg
15-23kg
23-40 kg
>40kg
Oseltamivir
30 mg once a day for 10 days after the last known exposure
45 mg once a day for 10 days after the last known exposure
60 mg once a day for 10 days after the last known exposure
75 mg once a day for 10 days after the last known exposure

Table 3. Recommended doses of oseltamivir antiviral medication for the treatment and prevention of S-OIV influenza for children less than 1 year of age.

Age
Recommended treatment dose
Recommended prophylaxis dose
<3 months
12 mg twice daily for 5 days
-
3-5 months
20mg twice daily for 5 days
20 mg once a day for 10 days
6-11 months
25 mg twice daily for 5 days
25 mg once a day for 10 days

Antiviral chemoprophylaxis with either oseltamivir or zanamivir is recommended for the following:

  1. Household close contacts who are at high-risk for complications of influenza (children younger  than 5 years old, pregnant women, persons =65 years-old and those with certain chronic medical  conditions) of a confirmed or suspected case.

  2. School children or daycare attendees who are at high-risk for complications of influenza (children  younger than 5 years old, pregnant women, persons =65 years-old and those with certain chronic  medical conditions) who had close contact (face-to-face) with a confirmed, probable, or suspected  case.

  3. Children who traveled to Mexico who are at high-risk for complications of influenza (children  younger than 5 years old pregnant women, persons =65 years-old and those with certain chronic  medical conditions).




 
 
Educational Section
 
Disclaimer:
The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
 
copyright ©2011 website design & development by Levioza
Follow Us
Follow us on :
Folllow Us